Long-term outcome of non-Stx–HUS patients
. | No mutation, no. . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P1 . | P2 . | P3 . |
|---|---|---|---|---|---|---|---|
| Patients with remission | 36 (84) | 9 (40) | 12 (14) | 2 (6) | .03 | .007 | <.001 |
| Patients with complete remission | 22 (36) | 3 (9) | 4 (12) | 2 (2) | .13 | .09 | >.999 |
| Patients with complete remission, after recurrences | 14 (36) | 6 (9) | 8 (12) | 0 (2) | .13 | .09 | >.999 |
| Patients with no remission | 48 (84) | 31 (40) | 2 (14) | 4 (6) | .03 | .003 | <.001 |
| Chronic renal insufficiency | 5 (48) | 3 (31) | 0 (2) | 0 (4) | .91 | .63 | .64 |
| ESRF | 32 (48) | 13 (31) | 2 (2) | 4 (4) | .03 | .32 | .29 |
| Death | 11 (48) | 15 (31) | 0 (2) | 0 (4) | .019 | .44 | .18 |
. | No mutation, no. . | CFH mutation, no. . | MCP mutation, no. . | IF mutation, no. . | P1 . | P2 . | P3 . |
|---|---|---|---|---|---|---|---|
| Patients with remission | 36 (84) | 9 (40) | 12 (14) | 2 (6) | .03 | .007 | <.001 |
| Patients with complete remission | 22 (36) | 3 (9) | 4 (12) | 2 (2) | .13 | .09 | >.999 |
| Patients with complete remission, after recurrences | 14 (36) | 6 (9) | 8 (12) | 0 (2) | .13 | .09 | >.999 |
| Patients with no remission | 48 (84) | 31 (40) | 2 (14) | 4 (6) | .03 | .003 | <.001 |
| Chronic renal insufficiency | 5 (48) | 3 (31) | 0 (2) | 0 (4) | .91 | .63 | .64 |
| ESRF | 32 (48) | 13 (31) | 2 (2) | 4 (4) | .03 | .32 | .29 |
| Death | 11 (48) | 15 (31) | 0 (2) | 0 (4) | .019 | .44 | .18 |
IF mutation group has not been included in statistical analysis. The numbers of patients for whom data were available are reported in parentheses.
P1 indicates no mutation versus CFH mutation; P2, no mutation versus MCP mutation; and P3, CFH mutation versus MCP mutation.